Download PDF
Thromb Haemost 1982; 47(03): 265-268
DOI: 10.1055/s-0038-1657182
Original Article
Schattauer GmbH Stuttgart

The Inhibition of Tissue Activator and Urokinase by Human Plasma

J E Walker
The Department of Physiology, University of Aberdeen, Aberdeen, Scotland
,
D Ogston
The Department of Physiology, University of Aberdeen, Aberdeen, Scotland
› Author Affiliations
Further Information

Publication History

Received 18 March 1982

Accepted 22 April 1982

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Plasma reduced the activity of urokinase and, to a lesser extent, tissue activator on unheated fibrin plates. After depletion of plasminogen by lysine-Sepharose the inhibitory effect of plasma was increased.

Normal plasma separated on DEAE-Sepharose or, after passage through lysine-Sepharose, on Sephadex G-100 provided fractions in three regions capable of inhibiting tissue activator. The high molecular weight fractions inhibited both activators, but after plasma fractionation on Sephadex 4B the inhibitory activities against tissue activator and urokinase eluted separately. Urokinase inhibition eluted with a2-macroglobulin: the inhibition of tissue activator was of higher molecular weight and of greater lability. Inhibition of tissue activator was found in two lower molecular weight regions: the fractions of one region inhibited tissue activator and coincided with the elution of fast-acting antiplasmin activity. The other region inhibited both tissue activator and urokinase. Alpha1 antitrypsin and antithrombin III eluted after both inhibitory regions.

Key words

Urokinase - Tissue activator - Plasma inhibitors of fibrinolysis
 

  • References

  • 1 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activator in blood and vascular wall. Thromb Res 1980; 18: 815-830
    CrossrefPubMedGoogle Scholar
  • 2 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedGoogle Scholar
  • 3 Rickli EE, Zaugg H. Isolation and purification of highly enriched tissue plasminogen activator from pig heart. Thrombos Diathes Haemorrh 1970; 23: 64-76
    PubMedGoogle Scholar
  • 4 Harpel P PC. Human plasma ±2--macroglobulin: an inhibitor of plasma kallikrein. J Exp Med 1970; 132: 330-371
    PubMedGoogle Scholar
  • 5 Beattie AG, Ogston D, Bennett NB, Douglas AS. Inhibitors of plasminogen activation in human blood. Br J Haematol 1976; 32: 135-143
    CrossrefPubMedGoogle Scholar
  • 6 Bennett NB. A method for the quantitative assay of inhibitor of plasminogen activation in human serum. Thrombos Diathes Haemorrh 1967; 17: 12-22
    PubMedGoogle Scholar
  • 7 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Int J Immunochem 1965; 2: 235-238
    CrossrefPubMedGoogle Scholar
  • 8 Brakman P, Astrup T. Selective inhibition in human pregnancy blood of urokinase induced fibrinolysis. Scand J Clin Lab Invest 1963; 15: 603-609
    CrossrefPubMedGoogle Scholar
  • 9 Thorsen S. The inhibition of tissue plasminogen activator and urokinase-induced fibrinolysis by some natural proteinase inhibitors and by plasma and serum from normal and pregnant subjects. Scand J clin Lab Invest 1973; 31: 51-59
    CrossrefPubMedGoogle Scholar
  • 10 Hedner U, Nilsson IM, Jacobsen CD. Demonstration of low content of fibrinolytic inhibitors in individuals with high fibrinolytic capacity. Scand J Clin Lab Invest 1970; 25: 329-336
    CrossrefPubMedGoogle Scholar
  • 11 Aoki N, von Kaulla KN. Human serum plasminogen antiactivator: its distinction from antiplasmin. Am J Physiol 1971; 220: 1137-1145
    PubMedGoogle Scholar
  • 12 Hedner U. Studies on an inhibitor of plasminogen activation in human serum. Thrombos Diathes Haemorrh 1973; 30: 414-424
    PubMedGoogle Scholar
  • 13 Hedner U, Martinsson G. Inhibition of activated Hageman factor by an inhibitor of the plasminogen activation. Thromb Res 1978; 12: 1015-1023
    CrossrefPubMedGoogle Scholar
  • 14 Seigel-Ralston A, Astrup T. A previously undescribed fibrinolysis inhibitor in human blood. Nature 1972; 234: 180-181
    PubMedGoogle Scholar
  • 15 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. J Biol Chem 1980; 255: 10214-10222
    PubMedGoogle Scholar
  • 16 Ogston D, Bennett B, Herbert RJ, Douglas AS. The inhibition of urokinase by ±2-macroglobulin. Clin Sci 1973; 44: 73-79
    CrossrefPubMedGoogle Scholar
  • 17 Clemmensen I, Christensen U. Inhibition of urokinase by complex formation with human ±1-antitrypsin. Biochim Biophys Acta 1976; 249: 591-599
    PubMedGoogle Scholar
  • 18 Clemmensen I. Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin. Thromb Haemostas 1978; 39: 616-623
    PubMedGoogle Scholar
  • 19 Crawford GPM, Ogston D. The influence of α1-antitrypsin on plasmin, urokinase and Hageman factor co-factor. Biochim Biophys Acta 1974; 354: 107-113
    CrossrefPubMedGoogle Scholar
  • 20 Crawford GPM, Ogston D. The action of antithrombin III on plasmin and activators of plasminogen. Biochim Biophys Acta 1975; 391: 189-192
    CrossrefPubMedGoogle Scholar
  • 21 Moroi M, Aoki N. The mechanism of reaction between α2-plasmin inhibitor (α2-antiplasmin) and enzymes. In: Collen D, Wiman B, Verstraete M. (Eds) The Physiological Inhibitors of Blood Coagulation and Fibrinolysis. 121-129 Elsevier Biomedical Press; Holland: 1979
    Google Scholar